1. Why was clopidogrel used in non-ST elevation myocardial infarction instead of ticagrelor considering the fact that ticagrelor has shown to have more beneficial effects in acute coronary syndrome, at least in the first instance?
1. 급성 관상동맥 증후군의 경우, 티카그렐러가 적어도 첫 번째 발생 시 더 많은 장점을 제공한다는 사실을 고려할 때 비ST 상승 심근 경색에 클로피도그렐을 사용한 이유는 무엇입니까?
1. Tại sao clopidogrel được sử dụng trong các trường hợp nhồi máu cơ tim tăng không ST thay cho ticagrelor dù rằng ticagrelor đã được chứng minh là có nhiều tác dụng có lợi hơn trong hội chứng mạch vành cấp tính, ít nhất là trong trường hợp đầu tiên?
1. Mengapa clopidogrel digunakan pada elevasi non-ST infark miokard ketimbang ticagrelor dengan mempertimbangkan fakta bahwa tigracelor telah terbukti memiliki efek manfaat lebih pada sindrom koroner akut, paling tidak pada kejadian pertama?
The Zena and Michael A. Wiener Cardiovascular
Institute, Icahn School of Medicine at Mount Sinai, USA
Jonathan Halperin is the Robert and Harriet Heibrunn Professor of
Medicine at The Mount Sinai School of Medicine, New York University
and Director of Clinical Cardiology in the Zena and Michael A. Wierner
Cardiovascular Institute at The Mount Sinai Medical Center.
Professor Halperin was awarded an MD from Boston University in
1975. He has previously served in various federal appointments which
included the Cardiovascular and Renal Drugs Advisory Committee of
the U.S. Food and Drug Administration and the National Institutes of
Health where he was in the Data Safety Monitoring board for the clinical trial of aspirin and
simvastatin in pulmonary arterial hypertension and in the clinical trial coordinating centre of
the National Institutes of Health. He was the principal cardiologist who spearheaded the SPAF
(Stroke Prevention in Atrial Fibrillation clinical trials). The trials were conducted in multiple
centres where 3,600 patients and more than 100 investigators were involved. Currently, he is
involved in several clinical trials with the objective of developing more effective drugs for the
prevention of ischemia in a range of cardiovascular disease conditions.
Professor Halperin has authored a wide range of materials including over 100 peer-reviewed
reports, books, chapters, guidelines and position statements, invited articles and reviews, clinical
case reports, and abstracts. His numerous awards and honours include the Champion of Heart
and Stroke, Master of the Society for Vascular Medicine, The Heart of New York Award, The
Heart of New York Presidential Salute, Howard B. Sprague Research Fellowship Award, Samuel
Bronfman Department of Medicine Teaching Excellence, Samuel Bronfman Department of
Medicine Grand Rounds Award, Cardiology Fellows Society of Greater New York, The Simon
Dack Award, The Jacobi Medallion, The Solomon R. Berson Memorial Award, John R. Murray
Award, The University Hospital Chair and the Roland Jackson Memorial Medical Scholarship.
Dr. Raymond Wong is Honorary Clinical Associate Professor and Head of the Division of Haematology at the Department of Medicine & Therapeutics of the Chinese University of Hong Kong. He is also Consultant in the Department of Medicine and Therapeutics at the Prince of Wales Hospital, Hong Kong.
Dr. Wong received his medical degree from the Chinese University of Hong Kong and completed his training at Prince of Wales Hospital, Hong Kong in Haematology and Haematological Oncology, Internal Medicine and Clinical Pharmacology and Therapeutics. Dr. Wong undertook his Blood and Marrow Transplantation Fellowship training at the MD Anderson Cancer Center, Texas, USA and gained a Doctor of Medicine at the Chinese University of Hong Kong.
Dr. Wong has broad research interests with a special focus on the biological and therapeutic aspects of leukaemias, autoimmune haematological diseases, stem cell transplantation, bleeding and thrombosis. He served as the Chairman of the Hong Kong Association of Blood Transfusion and Haematology from 2004 to 2005. Dr. Wong is the author or co-author of over 100 peer-reviewed articles, published in international journals such as Blood, Circulation, JAMA and the New England Journal of Medicine.
The Zena and Michael A. Wiener Cardiovascular
Institute, Icahn School of Medicine at Mount Sinai, USA
Dr. Raymond Wong is Honorary Clinical Associate Professor and Head of the Division of Haematology at the Department of Medicine & Therapeutics of the Chinese University of Hong Kong. He is also Consultant in the Department of Medicine and Therapeutics at the Prince of Wales Hospital, Hong Kong.